Real-world practice patterns of 177Lu-DOTATATE in neuroendocrine tumours: A GTE national survey

#4360

Introduction: 177Lu-DOTATATE is a standard treatment for neuroendocrine tumours. Grade 3/4 hematologic toxicity affects about 5-10% of patients, with a 2-4% risk of secondary malignant hematologic disorders.

Aim(s): To assess real-world practices of 177Lu-DOTATATE focusing on haematological toxicity.

Materials and methods: An anonymous national survey consisting of 45 single- or multiple-choice questions.

Conference:

Presenting Author:

Authors: Oziel-Taieb S, Ansquer C, Deshayes E, Haissaguerre M,

Keywords: 177Lu-DOTATATE, haematological toxicity, thrombocytopenia, neuroendocrine tumour, toxicity management,